etidronate has been researched along with Rheumatoid Arthritis in 26 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 9.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "To investigate the effect of intermittent cyclical etidronate treatment on radiographic progression, bone collagen markers, and clinical disease activity in patients with rheumatoid arthritis (RA)." | 9.10 | Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. ( Friman, C; Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 9.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| " We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis." | 9.06 | A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988) |
| "This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro." | 7.73 | Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. ( Nagashima, M; Shue, G; Yamamoto, K; Yoshino, S, 2006) |
| "Etidronate was effective at inhibiting bone resorption and destruction in study patients with RA, while not increasing BAP concentrations; and a correlation was observed between the concentration of DPD and IL-6, indicating the antiinflammatory effect of etidronate." | 6.71 | Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. ( Hasegawa, J; Katsumata, S; Nagashima, M; Nishijima, T; Yamamoto, M; Yoshino, S, 2003) |
| "Kynurenine analysis was performed by HPLC." | 5.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 5.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "To investigate the effect of intermittent cyclical etidronate treatment on radiographic progression, bone collagen markers, and clinical disease activity in patients with rheumatoid arthritis (RA)." | 5.10 | Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. ( Friman, C; Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 5.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| " We used a randomized placebo-controlled design to evaluate the efficacy of one-year cyclical etidronate therapy in preventing bone loss in 83 glucocorticoid-treated patients with rheumatoid arthritis, polymyalgia rheumatica, or giant cell arteritis." | 5.09 | Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. ( Barton, I; Bonvoisin, B; Cortet, B; Hachulla, E; Roux, C, 1999) |
| "A double blind, randomised placebo controlled study comparing cyclic etidronate and placebo during two years in 37 postmenopausal women receiving long term corticosteroid treatment, mainly for polymyalgia rheumatica (40% of the patients) and rheumatoid arthritis (30%)." | 5.08 | Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. ( Boonen, S; Dequeker, J; Geusens, P; Joly, J; Nijs, J; Raus, J; Stalmans, R; Vanhoof, J, 1998) |
| "Cohort study in a tertiary care university affiliated hospital in corticosteroid treated patients, with polymyalgia rheumatica, asthma, systemic lupus erythematosus, rheumatoid arthritis, or temporal arteritis, examining the effects of ICT etidronate." | 5.07 | Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. ( Adachi, J; Bensen, WG; Bianchi, F; Cividino, A; Craig, GL; Cranney, A; Goldsmith, CH; Kaminska, E; Papaioannou, A; Sebaldt, RJ, 1994) |
| " We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis." | 5.06 | A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988) |
| "This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro." | 3.73 | Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. ( Nagashima, M; Shue, G; Yamamoto, K; Yoshino, S, 2006) |
| "Osteoporosis is a common adverse reaction induced by glucocorticoid treatment." | 2.73 | Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. ( Ichimura, A; Iwata, H; Nakajima, T; Ochiai, H; Takagi, H; Toriyama, T; Tsuchiya, H; Yamada, S, 2007) |
| "Etidronate was effective at inhibiting bone resorption and destruction in study patients with RA, while not increasing BAP concentrations; and a correlation was observed between the concentration of DPD and IL-6, indicating the antiinflammatory effect of etidronate." | 2.71 | Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. ( Hasegawa, J; Katsumata, S; Nagashima, M; Nishijima, T; Yamamoto, M; Yoshino, S, 2003) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Kynurenine analysis was performed by HPLC." | 1.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (19.23) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 14 (53.85) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Laurent, AJ | 1 |
| Bindslev, N | 1 |
| Johansson, B | 1 |
| Berg, L | 1 |
| Valleala, H | 2 |
| Laasonen, L | 2 |
| Koivula, MK | 2 |
| Mandelin, J | 2 |
| Friman, C | 1 |
| Risteli, J | 2 |
| Konttinen, YT | 2 |
| Hasegawa, J | 1 |
| Nagashima, M | 3 |
| Yamamoto, M | 1 |
| Nishijima, T | 1 |
| Katsumata, S | 1 |
| Yoshino, S | 2 |
| Forrest, CM | 1 |
| Kennedy, A | 1 |
| Stone, TW | 1 |
| Stoy, N | 1 |
| Darlington, LG | 1 |
| Lange, U | 1 |
| Illgner, U | 1 |
| Teichmann, J | 1 |
| Schleenbecker, H | 1 |
| Yamamoto, K | 1 |
| Shue, G | 1 |
| Cruse, LM | 1 |
| Valeriano, J | 1 |
| Vasey, FB | 1 |
| Carter, JD | 1 |
| Yamada, S | 1 |
| Takagi, H | 1 |
| Tsuchiya, H | 1 |
| Nakajima, T | 1 |
| Ochiai, H | 1 |
| Ichimura, A | 1 |
| Iwata, H | 1 |
| Toriyama, T | 1 |
| Nakayama, H | 1 |
| Morishita, M | 1 |
| Wauke, K | 1 |
| Takahashi, H | 1 |
| Takenouchi, K | 1 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Oh, BK | 1 |
| Macfarlane, JD | 1 |
| Goei The, HS | 1 |
| Pauwels, EK | 1 |
| Bijvoet, OL | 1 |
| Frijlink, WB | 1 |
| Jie, K | 1 |
| van der Linden, H | 1 |
| Meijer, CJ | 1 |
| Mulder, H | 1 |
| van Paassen, HC | 1 |
| Reitsma, PH | 1 |
| te Velde, J | 1 |
| de Vries, E | 1 |
| van der Wey, JP | 1 |
| Adachi, J | 1 |
| Cranney, A | 1 |
| Goldsmith, CH | 1 |
| Bensen, WG | 1 |
| Bianchi, F | 1 |
| Cividino, A | 1 |
| Craig, GL | 1 |
| Kaminska, E | 1 |
| Sebaldt, RJ | 1 |
| Papaioannou, A | 1 |
| Disla, E | 1 |
| Tamayo, B | 1 |
| Fahmy, A | 1 |
| Geusens, P | 1 |
| Dequeker, J | 1 |
| Vanhoof, J | 1 |
| Stalmans, R | 1 |
| Boonen, S | 1 |
| Joly, J | 1 |
| Nijs, J | 1 |
| Raus, J | 1 |
| Cortet, B | 1 |
| Hachulla, E | 1 |
| Barton, I | 1 |
| Bonvoisin, B | 1 |
| Roux, C | 1 |
| Jenkins, EA | 1 |
| Walker-Bone, KE | 1 |
| Wood, A | 1 |
| McCrae, FC | 1 |
| Cooper, C | 1 |
| Cawley, MI | 1 |
| Eastell, R | 1 |
| Devogelaer, JP | 1 |
| Peel, NF | 1 |
| Chines, AA | 1 |
| Bax, DE | 1 |
| Sacco-Gibson, N | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Russell, RG | 1 |
| Solomon, DH | 1 |
| Kuntz, KM | 1 |
| Palmedo, H | 1 |
| Rockstroh, JK | 1 |
| Bangard, M | 1 |
| Schliefer, K | 1 |
| Risse, J | 1 |
| Menzel, C | 1 |
| Biersack, HJ | 1 |
| Halverson, PB | 1 |
| McCarty, DJ | 1 |
| Park, HM | 1 |
| Terman, SA | 1 |
| Ridolfo, AS | 1 |
| Wellman, HN | 1 |
| Bird, HA | 1 |
| Hill, J | 1 |
| Sitton, NG | 1 |
| Dixon, JS | 1 |
| Wright, V | 1 |
1 review available for etidronate and Rheumatoid Arthritis
| Article | Year |
|---|---|
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteop | 2007 |
14 trials available for etidronate and Rheumatoid Arthritis
| Article | Year |
|---|---|
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; Collagen Type I; Dis | 2003 |
Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Densi | 2003 |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Collagen Type I; Disease Progression; Dose-Respons | 2003 |
Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; C-Reactive Protein; Cross-Linking Reage | 2004 |
Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation | 2007 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; C | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Bone Density; Cohort Studies; Dose-Resp | 1994 |
Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
Topics: Aged; Analysis of Variance; Arthritis, Rheumatoid; Bone Density; Calcium; Double-Blind Method; Drug | 1998 |
Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Amino Acids; Arthritis, Rheumatoid; Bone Density; Doub | 1999 |
The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.
Topics: Absorptiometry, Photon; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Alkaline Phosphatase; Arth | 1999 |
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Bl | 2000 |
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.
Topics: Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; | 2001 |
A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Bone and Bones; Clinical Trials as Topic; E | 1988 |
11 other studies available for etidronate and Rheumatoid Arthritis
| Article | Year |
|---|---|
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Synergistic effects of ethanol and isopentenyl pyrophosphate on expansion of γδ T cells in synovial fluid from patients with arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cell Proliferation; Cell Survival; Drug Synergism; Ethanol; Etid | 2014 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexat | 2003 |
Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Densi | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation | 2006 |
Sequential joint scintigraphy in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Joints; Male; Middle Aged; Organ | 1983 |
APD in Paget's disease of bone. Role of the mononuclear phagocyte system?
Topics: Animals; Arthritis, Rheumatoid; Calcitonin; Clodronic Acid; Diphosphonates; Drug Therapy, Combinatio | 1980 |
Intermittent etidronate and corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Osteoporosis; | 1997 |
Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis.
Topics: Arthritis, Rheumatoid; Cost-Benefit Analysis; Estrogen Replacement Therapy; Etidronic Acid; Female; | 2000 |
Identification of hydroxyapatite crystals in synovial fluid.
Topics: Adult; Aged; Arthritis, Juvenile; Arthritis, Rheumatoid; Chondrocalcinosis; Etidronic Acid; Female; | 1979 |
A quantitative evaluation of rheumatoid arthritic activity with Tc-99m HEDP.
Topics: Adult; Arthritis, Rheumatoid; Etidronic Acid; Evaluation Studies as Topic; Female; Humans; Male; Mid | 1977 |